Comparative acute toxicity from whole breast irradiation using 3-week accelerated schedule with concomitant boost and the 6.5-week conventional schedule with sequential boost for early-stage breast cancer

Manjeet Chadha, Dan Vongtama, Patricia Friedmann, Celina Parris, Susan K. Boolbol, Rudolph Woode, Louis B. Harrison

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Background: We aimed to evaluate the incidence of acute toxicity in a 3-week accelerated radiation therapy (RT) schedule with a concomitant boost compared with the 6.5-week conventional schedule with a sequential boost for early-stage, node-negative breast cancer. Materials and Methods: This study included the first 50 patients treated on protocol using the accelerated schedule as well as 74 patients with comparable stages of disease treated over the same period using the conventional schedule. An accelerated schedule of 40.5 Gy × 2.7 Gy/fraction to the whole breast with 4.5 Gy × 0.3 Gy/fraction concomitant boost, for a delivered total dose of 45.0 Gy × 3.0 Gy/fraction in 15 fractions to the lumpectomy site. The conventional schedule used 46.8 Gy × 1.8 Gy to the whole breast with a sequential boost of 14.0 Gy × 2.0 Gy/fraction, delivering a total dose of 60.8 Gy × 33 fractions to the lumpectomy site. The side effects observed during RT and through the initial 8 weeks after treatment were scored for acute toxicity. Results: A lower incidence of < grade 2 skin toxicity was observed among patients treated on the accelerated schedule compared with those treated on the conventional schedule (p =.0015). There was a higher incidence of breast pain among patients receiving the conventional schedule (p =.045). No significant difference in the incidence of breast edema, fatigue, or hematologic side effects was observed between the 2 groups. Conclusion: Our observations suggest that there is acceptable toxicity with the accelerated schedule as used in this study. Further, it is not associated with a higher risk of acute toxicity when compared with the conventional schedule. Patients in the study are being followed, and clinical outcomes will be reported as the data mature.

Original languageEnglish (US)
Pages (from-to)57-62
Number of pages6
JournalClinical Breast Cancer
Volume12
Issue number1
DOIs
StatePublished - 2012

Fingerprint

Appointments and Schedules
Breast
Breast Neoplasms
Segmental Mastectomy
Incidence
Radiotherapy
Mastodynia
Fatigue
Edema
Skin

Keywords

  • Accelerated RT
  • Acute toxicity
  • Breast cancer
  • Whole-breast irradiation

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Comparative acute toxicity from whole breast irradiation using 3-week accelerated schedule with concomitant boost and the 6.5-week conventional schedule with sequential boost for early-stage breast cancer. / Chadha, Manjeet; Vongtama, Dan; Friedmann, Patricia; Parris, Celina; Boolbol, Susan K.; Woode, Rudolph; Harrison, Louis B.

In: Clinical Breast Cancer, Vol. 12, No. 1, 2012, p. 57-62.

Research output: Contribution to journalArticle

@article{92c4ac02714948b8bb0b27c1e8b86f19,
title = "Comparative acute toxicity from whole breast irradiation using 3-week accelerated schedule with concomitant boost and the 6.5-week conventional schedule with sequential boost for early-stage breast cancer",
abstract = "Background: We aimed to evaluate the incidence of acute toxicity in a 3-week accelerated radiation therapy (RT) schedule with a concomitant boost compared with the 6.5-week conventional schedule with a sequential boost for early-stage, node-negative breast cancer. Materials and Methods: This study included the first 50 patients treated on protocol using the accelerated schedule as well as 74 patients with comparable stages of disease treated over the same period using the conventional schedule. An accelerated schedule of 40.5 Gy × 2.7 Gy/fraction to the whole breast with 4.5 Gy × 0.3 Gy/fraction concomitant boost, for a delivered total dose of 45.0 Gy × 3.0 Gy/fraction in 15 fractions to the lumpectomy site. The conventional schedule used 46.8 Gy × 1.8 Gy to the whole breast with a sequential boost of 14.0 Gy × 2.0 Gy/fraction, delivering a total dose of 60.8 Gy × 33 fractions to the lumpectomy site. The side effects observed during RT and through the initial 8 weeks after treatment were scored for acute toxicity. Results: A lower incidence of < grade 2 skin toxicity was observed among patients treated on the accelerated schedule compared with those treated on the conventional schedule (p =.0015). There was a higher incidence of breast pain among patients receiving the conventional schedule (p =.045). No significant difference in the incidence of breast edema, fatigue, or hematologic side effects was observed between the 2 groups. Conclusion: Our observations suggest that there is acceptable toxicity with the accelerated schedule as used in this study. Further, it is not associated with a higher risk of acute toxicity when compared with the conventional schedule. Patients in the study are being followed, and clinical outcomes will be reported as the data mature.",
keywords = "Accelerated RT, Acute toxicity, Breast cancer, Whole-breast irradiation",
author = "Manjeet Chadha and Dan Vongtama and Patricia Friedmann and Celina Parris and Boolbol, {Susan K.} and Rudolph Woode and Harrison, {Louis B.}",
year = "2012",
doi = "10.1016/j.clbc.2011.09.002",
language = "English (US)",
volume = "12",
pages = "57--62",
journal = "Clinical Breast Cancer",
issn = "1526-8209",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Comparative acute toxicity from whole breast irradiation using 3-week accelerated schedule with concomitant boost and the 6.5-week conventional schedule with sequential boost for early-stage breast cancer

AU - Chadha, Manjeet

AU - Vongtama, Dan

AU - Friedmann, Patricia

AU - Parris, Celina

AU - Boolbol, Susan K.

AU - Woode, Rudolph

AU - Harrison, Louis B.

PY - 2012

Y1 - 2012

N2 - Background: We aimed to evaluate the incidence of acute toxicity in a 3-week accelerated radiation therapy (RT) schedule with a concomitant boost compared with the 6.5-week conventional schedule with a sequential boost for early-stage, node-negative breast cancer. Materials and Methods: This study included the first 50 patients treated on protocol using the accelerated schedule as well as 74 patients with comparable stages of disease treated over the same period using the conventional schedule. An accelerated schedule of 40.5 Gy × 2.7 Gy/fraction to the whole breast with 4.5 Gy × 0.3 Gy/fraction concomitant boost, for a delivered total dose of 45.0 Gy × 3.0 Gy/fraction in 15 fractions to the lumpectomy site. The conventional schedule used 46.8 Gy × 1.8 Gy to the whole breast with a sequential boost of 14.0 Gy × 2.0 Gy/fraction, delivering a total dose of 60.8 Gy × 33 fractions to the lumpectomy site. The side effects observed during RT and through the initial 8 weeks after treatment were scored for acute toxicity. Results: A lower incidence of < grade 2 skin toxicity was observed among patients treated on the accelerated schedule compared with those treated on the conventional schedule (p =.0015). There was a higher incidence of breast pain among patients receiving the conventional schedule (p =.045). No significant difference in the incidence of breast edema, fatigue, or hematologic side effects was observed between the 2 groups. Conclusion: Our observations suggest that there is acceptable toxicity with the accelerated schedule as used in this study. Further, it is not associated with a higher risk of acute toxicity when compared with the conventional schedule. Patients in the study are being followed, and clinical outcomes will be reported as the data mature.

AB - Background: We aimed to evaluate the incidence of acute toxicity in a 3-week accelerated radiation therapy (RT) schedule with a concomitant boost compared with the 6.5-week conventional schedule with a sequential boost for early-stage, node-negative breast cancer. Materials and Methods: This study included the first 50 patients treated on protocol using the accelerated schedule as well as 74 patients with comparable stages of disease treated over the same period using the conventional schedule. An accelerated schedule of 40.5 Gy × 2.7 Gy/fraction to the whole breast with 4.5 Gy × 0.3 Gy/fraction concomitant boost, for a delivered total dose of 45.0 Gy × 3.0 Gy/fraction in 15 fractions to the lumpectomy site. The conventional schedule used 46.8 Gy × 1.8 Gy to the whole breast with a sequential boost of 14.0 Gy × 2.0 Gy/fraction, delivering a total dose of 60.8 Gy × 33 fractions to the lumpectomy site. The side effects observed during RT and through the initial 8 weeks after treatment were scored for acute toxicity. Results: A lower incidence of < grade 2 skin toxicity was observed among patients treated on the accelerated schedule compared with those treated on the conventional schedule (p =.0015). There was a higher incidence of breast pain among patients receiving the conventional schedule (p =.045). No significant difference in the incidence of breast edema, fatigue, or hematologic side effects was observed between the 2 groups. Conclusion: Our observations suggest that there is acceptable toxicity with the accelerated schedule as used in this study. Further, it is not associated with a higher risk of acute toxicity when compared with the conventional schedule. Patients in the study are being followed, and clinical outcomes will be reported as the data mature.

KW - Accelerated RT

KW - Acute toxicity

KW - Breast cancer

KW - Whole-breast irradiation

UR - http://www.scopus.com/inward/record.url?scp=84856060108&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856060108&partnerID=8YFLogxK

U2 - 10.1016/j.clbc.2011.09.002

DO - 10.1016/j.clbc.2011.09.002

M3 - Article

VL - 12

SP - 57

EP - 62

JO - Clinical Breast Cancer

JF - Clinical Breast Cancer

SN - 1526-8209

IS - 1

ER -